Document ID: chunk:federal_register_of_legislation:F2025L00049:schedule:3:p7
Version: federal_register_of_legislation:F2025L00049
Segment Type: schedule
Provision Reference: sch 3 (pt 7/8)
Character Range: 176327–179218

of granules except when included in or expressly excluded from Schedule 2; or
 (g) in individually wrapped powders or sachets of granules enclosed in a primary pack containing more than 50 wrapped powders or sachets of granules intended only as a bulk medicine pack and labelled "For dispensing only" and "This pack is not to be supplied to a patient"; or
 (h) in liquid preparations for oral use except when in Schedule 2.
PHENIRAMINE in oral preparations except:
 (a) when included in Schedule 2; or
 (b) for the treatment of children under 2 years of age.
PODOPHYLLOTOXIN in preparations containing 1% or less of podophyllotoxin for human use for the treatment of warts other than anogenital warts except when included in Schedule 2.
PODOPHYLLUM EMODI (podophyllin) in preparations containing 20% or less of podophyllin for human use for the treatment of warts other than anogenital warts except when included in Schedule 2.
PODOPHYLLUM PELTATUM (podophyllin) in preparations containing 20% or less of podophyllin for human use for the treatment of warts other than anogenital warts except when included in Schedule 2.
PROCHLORPERAZINE in divided preparations for oral use in packs containing not more than 10 dosage units for the treatment of nausea associated with migraine.
PROMETHAZINE in oral preparations except:
 (a) when included in Schedule 2; or
 (b) in preparations for the treatment of children under 2 years of age.
PSEUDOEPHEDRINE (other than preparations for stimulant, appetite suppression or weight‑control purposes) when supplied in a primary pack:
 (a) in liquid preparations containing 800 mg or less of pseudoephedrine hydrochloride (or its equivalent); or
 (b) in other preparations containing 720 mg or less of pseudoephedrine hydrochloride (or its equivalent).
RABEPRAZOLE in oral preparations containing 10 mg or less of rabeprazole per dosage unit for the relief of heartburn and other symptoms of gastro‑oesophageal reflux disease, in packs containing not more than 14 days' supply except when included in Schedule 2.
RIZATRIPTAN when in divided oral preparations containing 5 mg or less per dosage unit and when sold in a pack containing not more than 2 dosage units for the acute relief of migraine in patients who have a stable, well‑established pattern of migraine symptoms.
SALBUTAMOL as the only therapeutically active substance:
 (a) in metered aerosols delivering 100 micrograms or less of salbutamol per metered dose; or
 (b) in dry powders for inhalation delivering 200 micrograms or less of salbutamol per dose.
SALICYLIC ACID in preparations for dermal use except in preparations containing 40% or less of salicylic acid.
SANTONIN.
SODIUM PHOSPHATE in preparations for oral use for bowel cleansing prior to diagnostic medical and surgical procedures.
SODIUM PICOSULFATE in preparations for oral use for bowel cleansing prior to diagnostic medical or